NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Monday that its second-quarter revenues inched up 1 percent as a decline in systems and consumables sales was offset by a sharp rise in assay revenue.

The Austin, Texas-based firm reported total revenues of $48.3 million for the three months ended June 30, compared to $47.7 million for the second quarter of 2011. It missed Wall Street's consensus estimate for revenues of $49.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.